Floatz logo

16.ALPHA.-FLUOROESTRADIOL

Estrogen Receptor Positive Breast Cancer

University of UtahSmall moleculePhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
95/ 100

Competitive context

77 Active assets in the Estrogen Receptor Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Capivasertib
Imperial College London
Phase 2BB

View all 50 →

Same molecule, other indications

16.ALPHA.-FLUOROESTRADIOL is also rated in:

breast cancerDormant
B
Indicative ·
56 / 100
View asset →
ductal breast carcinoma in situDormant
CCC
Indicative ·
48 / 100
View asset →
breast cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →